IXICO Stock

IXICO AAQS

The The AAQS of IXICO (IXI.L) as of Aug 10, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

IXICO has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock IXICO in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API

IXICO Stock analysis

What does IXICO do? IXICO PLC is a leading company in the field of digital biomarker and data services in clinical development. The company was originally founded in London in 2004 and has since had a successful history in neurology and psychiatry research. IXICO's core competency lies in developing and commercially implementing innovative solutions in the field of digital biomarker analysis, data capture, and processing. Through the use of advanced image analysis, structural analysis, and cognitive assessment technologies, IXICO enables effective clinical development of drugs and therapies, particularly in the areas of neurological and psychiatric disorders. IXICO is organized into three main divisions: Digital Healthcare Analytics (DHA), Data Analytics Services (DAS), and Clinical Trial Technology Solutions (CTTS). Each division includes its own products and services tailored to meet the specific requirements and needs of customers. The Digital Healthcare Analytics division focuses on developing biomarker-based clinical software-as-a-service (SaaS) solutions. These are used for monitoring and diagnosing neurological disorders such as Alzheimer's, Parkinson's, and schizophrenia. The solutions developed are tailored to the needs of clinics, research institutions, and biopharmaceutical companies and significantly contribute to the improvement of patient analysis and treatment. The Data Analytics Services division includes a wide range of services for data capture, processing, and analysis. This includes, for example, image and data analysis of clinical data, support for sponsors in data management and study monitoring, as well as consulting and training services. The purpose of this division is to help sponsors work in compliance with regulatory requirements and best practices in the pharmaceutical industry. IXICO's Clinical Trial Technology Solutions division offers a range of technology solutions to support the clinical research of pharmaceutical and biotechnology companies. This includes software solutions such as Neurostatus.net, a neurostatus toolkit for digital assessment of neurological patients, and TrialTracker, a SaaS solution that supports sponsors in the planning and conduct of studies. With its pioneering products and services, IXICO has numerous customers worldwide, including large pharmaceutical and biotech companies. The company also has partnerships with some of the most renowned academic institutions in Europe and North America and is proud to have been part of some of the most significant clinical studies in the field of neurology in recent years. Under the leadership of founder and CEO Derek Hill, IXICO has built an experienced and highly qualified team of scientists and industry experts over the years. The employees come from a variety of disciplines and industries and work closely together to develop innovative solutions and meet customer needs. The company expects to continue successfully focusing on the development of technology-based solutions in clinical research in the future. IXICO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IXICO stock

The AAQS of IXICO is 4 in 2026.

On Eulerpool you can find the complete historical development of The AAQS IXICO since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

Quality — IXICO

All Key Metrics — IXICO